First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/23/2026

1. USO
2. META
3. NVDA
4. SPY
5. DCOY
6. MSFT
7. VKTX
8. PRGS
9. DGX
10. IONQ

Go back to First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy
(NASDAQ: VERU) Delayed: 2.50 +0.06 (2.46%)
Previous Close $2.44    52 Week High $ 
Open $2.46    52 Week Low $ 
Day High $2.52    P/E N/A 
Day Low $2.42    EPS $ 
Volume 121,369